NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Ixekizumab

Last Revision: February 15, 2021.

Estimated reading time: 1 minute

CASRN: 1143503-69-8

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of ixekizumab during breastfeeding. Because ixekizumab is a large protein molecule with a molecular weight of 146,000 Da, absorption by the infant is unlikely after the first few weeks postpartum, and it will probably be destroyed in the infant's gastrointestinal tract. Some professional guidelines feel that the drug is acceptable to use during breastfeeding.[1] Until more data become available, ixekizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Psoriasis) Adalimumab, Etanercept, Infliximab, Phototherapy, Tretinoin

References

1.
Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: A rapid update. Br J Dermatol. 2020;183:628–37. [PubMed: 32189327]

Substance Identification

Substance Name

Ixekizumab

CAS Registry Number

1143503-69-8

Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal, Humanized

Dermatologic Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Similar articles in PubMed

  • Review Reslizumab[Drugs and Lactation Database (...]
    Review Reslizumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Secukinumab[Drugs and Lactation Database (...]
    Review Secukinumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Natalizumab[Drugs and Lactation Database (...]
    Review Natalizumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Obiltoxaximab[Drugs and Lactation Database (...]
    Review Obiltoxaximab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Tildrakizumab[Drugs and Lactation Database (...]
    Review Tildrakizumab
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...